Navigation Links
Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
Date:10/9/2009

statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including SGX201, orBec® and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Medelis Expands CRO Services to Medical Devices, Appoints Dr. Inder Makin as VP
3. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
4. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
5. BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers
6. Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales
7. Seambiotic Appoints New CEO
8. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
9. Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board
10. ABRISA Appoints Jim Veler as President/CEO
11. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 4, 2015 Trigemina, Inc., a biopharmaceutical company ... delivered, analgesic drug products, announced today that the company ... of chief medical officer. Dr. Kori brings over 30 ... which has been focused in the neuroscience and headache ... Kori to our clinical team given his vast experience ...
(Date:8/4/2015)... , August 4, 2015 ... , online-only journal serving ... , a world-leading provider of scientific, technical, and medical ... the International Journal of Surgery Open ... journal covering all areas of surgery. This peer-reviewed, online-only ...
(Date:8/4/2015)... CARLOS, Calif. , Aug. 4, 2015  Natera, ... genetic testing and the analysis of circulating cell-free DNA, ... second quarter ended June 30, 2015 after the market ... conference call and webcast at 1:30 p.m. PT (4:30 ... and financial outlook.Event:Natera,s Second Quarter 2015 Results Conference Call  ...
(Date:8/4/2015)... 4, 2015   California Cryobank Stem Cell Services ... LifeLine Cryogenics, an east coast cord blood and reproductive ... tristate area. LifeLine clients will maintain full ... will be honored. Since 1991, LifeLine has ... of sperm, eggs, embryos, and cord blood stem cells. LifeLine ...
Breaking Biology Technology:Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 2Trigemina Appoints Dr. Shashi Kori to the Position of Chief Medical Officer 3Elsevier Announces the Launch of International Journal of Surgery Open 2Elsevier Announces the Launch of International Journal of Surgery Open 3Elsevier Announces the Launch of International Journal of Surgery Open 4Natera to Release Second Quarter 2015 Results on August 12, 2015 2FamilyCord Announces Acquisition of LifeLine Cryogenics 2
... 1 Baxa Corporation announces its,2008 sponsorship for ... Wheeler (founder of MicroPhage Inc.) recognized Baxa, along ... Annual All-Member,Meeting held April 29th at the University ... of the CBSA since its inception. Company founder ...
... Brian T. Griffin,group president, health plans, of Medco Health ... the Deutsche Bank 33rd Annual Health Care,Conference on May ... Boston, will begin at,10:10 a.m. ET. In addition, Medco,s ... in a panel discussion on The Future of,Personalized Medicine ...
... N.J., May 1 Osteotech, Inc.,(Nasdaq: OSTE ), ... for,regenerative healing, announced today that revenue for the first ... million for the first,quarter of 2007. Revenue from the ... segments, was $17.6 million for the three,months ended March ...
Cached Biology Technology:Baxa Announces Colorado BioScience Association Sponsorship 2Baxa Announces Colorado BioScience Association Sponsorship 3Medco to Present at the Deutsche Bank 33rd Annual Health Care Conference 2Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10% 2Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10% 3Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10% 4Osteotech Posts First Quarter Earnings Per Share of $.05 on Revenue Growth of 10% 5
(Date:7/27/2015)...   Zynx Health ™, the market leader ... today announced that its ZynxCarebook ™ mobile ... smartphones and tablets. With this expansion, care team ... ZynxCarebook to securely exchange messages and share assessments ... to other care settings, and improve clinical outcomes ...
(Date:7/21/2015)... , July 21, 2015 Passwords ... as seen in the recent U.S. Office of ... solution to the infosec conundrum, but developers and ... stored. To address this dilemma, Biometrics-as-a-Service provider HYPR ... Biometric Tokenization SDK for third party integration. ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... Geo-microbiologists from Arizona State University have solved a ... cyanobacteria, bore their way into limestone, sand grains, ... of carbonate. According to the lead ... the mystery of what is "at the heart ...
... Researchers from the UC Davis Health System have found ... D are significantly reduced in patients in the Sacramento ... factors that affects about one in three U.S. adults ... The study is the first to examine ...
... Spanish . One of the worst pests ... its worldwide success partly to its larvae,s nasty, sticky blood. ... and his colleagues discovered this recently, working with CABI researchers ... could lead to development of ways to overcome these defenses ...
Cached Biology News:Mystery dissolves with calcium pump discovery 2Mystery dissolves with calcium pump discovery 3Study finds low vitamin-d levels in northern California residents with metabolic syndrome 2Study finds low vitamin-d levels in northern California residents with metabolic syndrome 3Study finds low vitamin-d levels in northern California residents with metabolic syndrome 4Predatory bugs can save cornfields 2
Goat polyclonal to JIK ( Abpromise for all tested applications). Antigen: Synthetic peptide: HKKDHVFIRDEAGHGD, corresponding to amino acids 396-411 of Human JIK. Entrez Gene ID: 51347 Swi...
Chicken polyclonal to DCTD ( Abpromise for all tested applications). Antigen: Full length protein (Human) Entrez GeneID: 1635 Swiss Protein ID: P32321...
Rab 3 Immunogen: Synthetic peptide corresponding to the N-terminal region of Rab 3 protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
Biology Products: